14 / 22
Page 75
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Breast Pathology and Cancer Diagnosis
6
th
World Congress and Expo on
July 25-26, 2018 | Vancouver, Canada
Medicinal Chemistry and Rational Drugs
20
th
International Conference on
&
Breast pathology, proof of principle studies, and drug development
Bassem Toeama
University of Toronto, Canada
H
uman Epidermal Growth Factor Receptor 2 (HER2), also known as ERBB-2, is a 185-kDa member of the erbB family of protein
kinase receptors that is widely expressed in breast tissue. Binding with the epidermal growth factor like ligands (EGF-like ligands)
will activate downstream signal transduction cascades as the MAPK, Akt, JNK, and JAK2/STAT3 pathways leading to cellular
differentiation, mobility, proliferation, and survival. Several cancers are associated with HER2 overexpression including 25-30% of
breast cancer invasive ductal carcinoma subtype. The role of histopathology in stage IV metastatic breast cancer has gone beyond
diagnosis. Breast pathology biomarkers act as important prognostic and predictive tools to treatment response. Phase I and phase II
proof of principle studies involved in the drug development process of anti- HER2 monoclonal antibodies, Tyrosine Kinase Inhibitors
(TKIs), and Antibody-Drug Conjugates (ADCs) use breast pathology biomarkers as endpoints.
bassem.toeama@mail.utoronto.caJ Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C3-052